Clinical Trials Directory

Trials / Terminated

TerminatedNCT00947674

A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)

Prospective, Randomized, Double-Blind, Sham Treatment Controlled Multicenter Study to Evaluate Efficacy and Safety of Cellsorba™EX Used for Leukocytapheresis (LCAP) in Patients With Steroid-Free, Active Ulcerative Colitis

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
52 (actual)
Sponsor
Asahi Kasei Medical Co., Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, randomized, double-blind, sham treatment controlled multicenter study.

Conditions

Interventions

TypeNameDescription
DEVICECellsorba EXconduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times

Timeline

Start date
2009-05-01
Primary completion
2012-01-01
Completion
2012-10-01
First posted
2009-07-28
Last updated
2012-12-06

Locations

10 sites across 6 countries: Czechia, Germany, Israel, Japan, Sweden, United Kingdom

Source: ClinicalTrials.gov record NCT00947674. Inclusion in this directory is not an endorsement.

A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC) (NCT00947674) · Clinical Trials Directory